Healthcare / BiotechnologyNasdaqGS
$6.55
-0.59 (-8.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 28% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-175.6M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
90/100
SEC 100%
Sin guardar todavía.
Market Cap
$339M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-188.7%
↓Gross Margin
88.1%
↑Debt/Equity
0.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
+32.0%
FCF CAGR
—
FCF margin
-74.1%
FCF / Net income
0.65x
Latest source
SEC-backed
Margin decomposition
Último año: revenue $170.4M · net income $-193.9M · FCF $-126.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025SEC | 2024SEC | 2023SEC | 2022SEC | 2021SEC | 2020SEC | 2019SEC | 2018SEC | 2017SEC | 2016SEC | 2015SEC | 2014SEC | 2013SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $170.4M | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M | $154.6M | $35.2M | $218.5M | $10.4M | $4.6M | $7.6M | $6.1M | $6.1M |
| Net Income | $-193.9M | $-193.9M | $-227.1M | $-263.5M | $-280.3M | $127.8M | $-111.3M | $-94.7M | $99.9M | $-73.2M | $-63.0M | $-22.8M | $-4.0M | $-5.4M |
| EBITDA | $-133.3M | $-133.3M | $-198.2M | $-239.5M | $-244.2M | $169.5M | $-110.8M | $-141.8M | $92.1M | $-73.2M | $-64.8M | $-23.1M | $-3.7M | $-4.8M |
| EPS | -3.76 | -3.76 | -4.59 | -6.02 | -6.50 | 2.91 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | — | — | — |
| Gross Margin | 88.1% | 88.1% | 59.7% | 58.8% | 51.6% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -94.6% | -94.6% | -280.0% | -297.1% | -233.2% | 34.0% | -77.1% | -422.9% | 40.3% | -730.2% | -1423.8% | -304.9% | -60.2% | -78.5% |
| Net Margin | -113.8% | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% | -268.9% | 45.7% | -704.0% | -1372.1% | -300.6% | -65.4% | -88.5% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 0.72 | 0.72 | 0.32 | 0.29 | 0.18 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.62 | 2.62 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-126.4M | $-126.4M | $-175.6M | $-228.4M | $-238.2M | $134.7M | $-80.9M | $-119.4M | $91.4M | $-65.2M | $-56.7M | — | — | — |
| Returns | ||||||||||||||
| ROE | -188.7% | -188.7% | -87.5% | -84.5% | -54.3% | 16.7% | -29.5% | -21.0% | 19.6% | -40.0% | -38.9% | -10.5% | -21.9% | -38.7% |
| Valuation | ||||||||||||||
| P/E | — | — | — | — | — | 3.63 | — | — | 3.86 | — | — | — | — | — |
| P/B | 5.30 | 5.30 | 2.01 | 1.48 | 0.88 | 0.61 | 1.04 | 0.86 | 0.76 | 1.72 | 1.72 | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | 104.5% | 104.5% | -7.7% | -19.9% | -76.0% | 204.3% | 338.7% | -83.9% | 2002.4% | 126.5% | -39.5% | 24.0% | 0.5% | — |
| EPS Growth | 18.1% | 18.1% | 23.8% | 7.4% | -323.4% | 197.7% | -15.5% | -194.5% | 211.4% | -2.9% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.59 → -3.76
Residual
-36.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.